drugset / Trial / NCT00092508

CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

NCT00092508

RandomizedParallel-groupDouble-blindTreatment

Summary

This dose comparison study, taking place at over 200 sites worldwide, will compare the dosing, safety and efficacy of an investigational medicine OPC-6535 to the dosing, safety and efficacy of Asacol ® in the maintenance of remission in subjects with ulcerative colitis.

Timeline

Start
2004-05
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesalamine Small molecule 800 mg
Subject Tetomilast Small molecule 25 mg
Subject Tetomilast Small molecule 50 mg

Indications